The Finance Minister, P Chidambaram has inaugurated Biocon Biopharmaceuticals, India largest multi-product Biologics facility at 'Biocon Park', Bommasandra Industrial Area - Phase IV.

The company established Biocon Biopharmaceuticals Pvt Ltd (BBPL) in collaboration with CIMAB, representing the Centre of Molecular Immunology, Cuba. The state-of-the-art cGMP compliant facility is designed to manufacture a broad range of novel and bio-similar therapeutic products through large scale cell-culture fermentation for the treatment of cancer, auto-immune and metabolic diseases, stated a release.

The facility is also designed to cater to contract manufacturing needs of international Bio-pharmaceutical companies. The company's multi-disciplinary technological capabilities & growing expertise in clinical development has enabled rapid advances in the field of protein therapeutics. The company believes that such novel products of biotechnology will provide quantum growth drivers for the future.

The 1,20,000 sft building spread over three floors comprises process, laboratory and technical support areas. The new facility represents a significant advancement in terms of technical sophistication over the Company's existing facilities and comprises three distinct modules-
Cell Culture Module for Monoclonal Antibodies and other cell culture products; Aseptic Formulation & Filling Module for sterile products in vials, cartridges, lyophils and syringes; Quality Control Module, added the release.

Commenting on the new facility, Kiran Mazumdar-Shaw, Chairman and Managing Director, of the company said, 'Biological drugs are increasingly gaining market share in the pharmaceutical sector. Monoclonals represent a new class of drugs called immuno therapeutics that are effectively addressing unmet medical needs especially in Oncology and autoimmune diseases. Biocon Biopharmaceuticals' immunotherapeutic portfolio is a comprehensive approach targeting both receptors (EGFR & HER1) and proliferation factors (EGF & TGF) aimed at complete remission and possible cure."